ISPOR Announces 2017-2018 Board of Directors

Published Jun 6, 2017
Princeton, NJ—June 6, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the election of the Society’s 2017-2018 Board of Directors. The new Board will assume office on July 1, 2017. The ISPOR Board of Directors are elected by its global membership. Shelby D. Reed, RPh, PhD assumes the role of president (2017-2018) after having served as the Society’s President-Elect. Dr. Reed is a professor at Duke University in Durham, NC, USA. Federico Augustovski, MD, MSc, PhD was elected to the position of president-elect (2017-2018). Dr. Augustovski is director of Health Economic Evaluations and Technology Assessment at the Institute for Clinical Effectiveness and Health Policy in Buenos Aires, Argentina. The following members were recently elected to the ISPOR Board of Directors for 3-year terms:
  • Meindert Boysen, PharmD, director for technology appraisal and highly-specialized technologies programs at the National Institute for Health and Care Excellence, London, England, UK
  • Stephanie R. Earnshaw, PhD, senior vice president, Health Economics at RTI Health Solutions, Raleigh-Durham, NC, USA
  • Jan Elias Hansen, PhD, vice president, Evidence for Access Unit, US Medical Affairs at Genentech, South San Francisco, CA, USA
Returning Board members include: Immediate Past President:
  • Lou Garrison, PhD, professor emeritus, Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy and adjunct professor, Departments of Global Health and Health Services at the University of Washington, Seattle, WA, USA
  • Zeba M. Khan, RPh, PhD, vice president at Celgene Corporation, Summit, NJ, USA—reappointed to a second three-year term
CEO and Executive Director:
  • Nancy S. Berg, CEO and executive director at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA
Returning Board Members:
  • Joanna Lis, MSc, MBAPhD,director, Market Access at Sanofi-Aventis, Warsaw, Poland
  • Gordon Liu, PhD, PKU Yangtze River Scholar professor of economics at Peking University National School of Development and director at PKU China Center for Health Economic Research, Beijing, China
  • Rosanna Tarricone, MScPhD,associate professor at Bocconi University, Milan, Italy
  • John Watkins, MPHPharmD, formulary manager at Premera Blue Cross, Mountlake Terrace, WA, USA


  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: | LinkedIn: | Twitter: (@ISPORorg) | YouTube: | Facebook:  

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now